Novo Nordisk's Avideh Nazeri discusses how a century's heritage remains relevant in such a competitive and fast-changing space

For almost a century, Danish diabetes giant Novo Nordisk (NOV: N) has been developing insulins and treatments for people with diabetes.

But in a space such as diabetes where so much has changed even when one looks at the last five to 10 years – from prevalence and understanding to treatments and the expanding number of drug companies competing in the field – is such a history of any benefit to the company?

"We are constantly building partnerships, enabling us to evolve as a company"